Business
Voyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugs
(NewsDirect) Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberm...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugs\n \n \n (NewsDirect)\n \n \n \n \n Voyageur Pharmaceuticals CEO Brent Willis\njoin's Proactive's Natalie Stoberman to share a significant\nlicensing agreement with Rain Cage Carbon to develop nanocarbon-based\ncontrast drugs for medical imaging.\n \n \n Willis says the partnership aims to develop new contrast agents\nfor the radiology drug market while also making Voyageur the first\ncarbon-neutral pharmaceutical company in the industry.\n \n \n He\nexplains that Rain Cage Carbon's innovative technology allows\nVoyageur to extract carbon dioxide and other emissions, generating\nhigh-grade carbon for various applications. By leveraging this\ntechnology, Willis says Voyageur plans to create safer and more\neffective drugs using carbon 60 molecules.\n \n \n \n Contact\nDetails\n \n \n \n Proactive Investors\n \n \n +1 604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":1407,"tagName":"div"}]